PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)
Recruiting
Phase 2
Interventional Study
Anemia
Coronary Disease
Coronary Artery Disease
Coronary Stenosis
Coronary Occlusion
Systemic Inflammatory Response
Bleeding
Epigenetic Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 120 (estimated)
- Sponsor
- Federal University of São Paulo · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Anemia poses risks during coronary artery bypass grafting (CABG), increasing complications and mortality rates. Blood transfusions in cardiac surgery have negative outcomes, prompting the use of erythropoietin in Patient Blood Management (PBM) to limit transfusion needs and enhance postoperative recovery. EPO can reduce blood component requirements, adverse events, and inflammation in anemic CABG …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Eletive surgery;
* Only CABG as procedure;
* Off pump CABG candidate.
Exclusion Criteria:
* Age \> 80 years;
* Chronic dialytic kidney disease;
* Chronic rheumatologic disease;
* Men with Hb levels \> 13 g/dl and \< 8g/dl;
* Women with Hb levels \> 12 g/dl and \< 8g/dl;
* Pr…
Contacts
No contact information available.